natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to claim 1 wherein the ginseng extract has a ginsenoside content of 8% with a ginsenoside Rg1/ginsenoside Rb1 ratio of 0.5/1, the Zingiber officinale extract has a gingerol content of 30% and the Echinacea angustifolia extract has an isobutylamide content higher than 20% by weight. 
Pripravci prema patentnom zahtjevu 1 ili 2, naznačeni time da je u ekstraktu ginsenga sadržaj ginsenozida 8%, a omjer ginsenozida Rgl/ginsenozida Rb1 jest 0.5/1, da je u ekstraktu Zingiber officinale sadržaj gingerola 30% te da je u ekstraktu Echinacea angustifolia sadržaj izobutilamida veći od 20% po masi.
Other additional features are possible. 
Moguća su i dodatna svojstva.
Hydrogen uptake ceased within the 2 hour reaction period. 
Potrošnja vodika prestaje tijekom reakcijskog perioda od 2 sata.
The compound of claim 1, having the Formula III: or Formula IV: or a pharmaceutically acceptable salt thereof. 
Tvar iz patentnog zahtjeva 1, ima formulu III: [image] ili formulu IV:
The structure according to Claim 1 or Claim 2, characterized in that said lateral walls (15) delimit said flow section (20; 320) extending it to the entire width of the stream bed (12). 
Struktura u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što navedene bočne stijenke (15) omeđuju navedeni dio vodenog toka (20; 320), šireći ga do cijele širine korita vodene struje (12).
filling the ingredient mix into packaging, and heating the ingredient mix in the packaging to a temperature in the range of from 90 to 155°C, maintaining the ingredient mix at the temperature selected in g) for a time period in the range of from 30 seconds to 9 hours, thereby forming a sliceable dairy food product. 
€) homogeniziranje mješavine sastojaka; 1) punjenje ambalaže mješavinom sastojaka, 1 2) zagrijavanje mješavine sastojaka u ambalaži, na temperaturu u rasponu od 90*C do 155*C, h) držanje mješavine sastojaka na temperaturi odabranoj u g) tijekom vremenskog perioda u rasponu od 30 sekundi do 9 sati, čime se oblikuje mliječni prehrambeni proizvod koji se može rezati.
In addition, the entire length of article or any portion thereof may be overwrapped with cigarette paper. 
Dalje, cijela dužina proizvoda ili njegov dio može biti omotan sa cigaret papirom.
2.0 mL of methyl iodide (32.00 mmol) were added all at once, the mixture covered and stirred for 2 hours at room temperature. 
Odjednom se doda 2,0 mL metil jodida (32,00 mmola), smjesu se pokrije i miješa 2 sata pri sobnoj temperaturi.
It is also preferred that R3 and R4, which may be the same or different, each represents a hydrogen atom, a halogen atom, trifluoromethyl, a straight or branched alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl group; a straight or branched alkoxyl group; or a straight or branched alkylthio group, or R3 and R4, together, represent an, optionally aromatic or heterocyclic, ring having the carbons to which they are attached forming a part of said ring, and being optionally further substituted by substituents b, 
Rs i Ra, koji mogu biti isti ili različiti, svaki predstavlja atom vodika, atom halogena, hidroksilnu skupinu, trifluorometil, ravni ili razgranati alkil, alkenil, alkinil, hidroksialkil, haloalkil, haloalkenil, ili haloalkinil skupinu; ravnu ili razgranatu alkoksil skupinu; ili ravnu ili razgranatu alkiltio skupinu, Rz i Ru, zajedno, predstavljaju, proizvoljno aromatski ili heterociklički prsten koji ima atome ugljika na koji su spojeni koji tvore dio navedenog prstena, te su nadalje proizvoljno supstituirani sa supstituentima b,
In one embodiment, the present invention contemplates a composition comprising the Sendai viral vector as described herein and a pharmaceutically acceptable carrier or diluent or any carrier, adjuvant or diluent. 
Pripravak, naznačen time što sadrži virus Sendai kao vektor u skladu s bilo kojim od patentnih zahtjeva 1-8, kao i farmaceutski prihvatljiv nosač ili razrjeđivač, ili bilo koji nosač, adjuvans ili razrjeđivač.
The use of the system according to claim 1, wherein the second composition of the second component of the system comprises the at least one enzyme-activating agent consisting essentially of a solvent. 
Upotreba sustava u skladu sa zahtjevom 1, naznačena time, što se drugi sastav od druge komponente sustava sastoji od najmanje jednog sredstva aktiviranja enzima koji u osnovi se sastoji od otapala.
The method of claim 1, wherein if the size of the transform unit is equal or smaller than 8×8, the inverse scan pattern is determined by the intra prediction mode. 
Postupak prema Zahtjevu 1, gdje je veličina transformacijske jedinice jednaka ili manja od 8x8, obrazac inverznog skeniranja se određuje na osnovi intrapredikcijskog režima.
oligofructose, resistant maltodextrin, inulin and polydextrose, in fixed ratios. 
oligofruktozu, rezistentni maltodekstrin, inulin 1 polidekstrozu u fiksnim omjerima.
Formulation for anticorrosion paints and coatings according to claim 1, wherein the viscosity of the formulation is lower than 40000 mPa·s. 
Sastav za antikorozivne slike i premaze sukladno zahtjevu 1, naznačeno time da je viskoznost sastava manja od 40000 mPa.s.
Add 5 mL Membrane Scrape Buffer and scrape cells. 
Dodaj 5 mL Membran Scrape pufera i sastruži stanice.
commencing tumour resection surgery on said patient; 
(b) početak operacije resekcije tumora na navedenom pacijentu;
A compound of Formula 1 wherein X is O. 
Spoj formule 1, R? l u kojem
is a group represented by the formula: 
3] je skupina predstavljena formulom:
Pharmaceutical compositions contain, e.g., from about 0.1% to about 99.9%, preferably from about 20% to about 60%, of the active ingredients. 
Farmaceutski sastavi sadrže, npr. od približno 0,1 % do približno 99,9%, ponajprije od približno 20% do približno 60% aktivnog sastojka.
In a preferred embodiment, the construct is an inducible genomic meganuclease expression construct that can be induced to express the meganuclease-encoding nucleic acid in a germ cell. 
Postupak sukladno patentnom zahtjevu 1, naznačena time, da je meganukleaza osigurana u konstruktu ekspresije koju je moguće regulirati.
each peripheral post comprising at least one plant-controller electronic card (CdE), which controls a plurality of plant-interface cards (IE) that supply the plants (E) directly, via a field bus (B1), on the basis of the commands received from the plant controller and acquire the control signals from the field sensors, transferring them to the controller, said system comprising: 
gdje svako periferno mjesto ima najmanje jednu elektronsku karticu upravljača opreme (CdE), koja upravlja više kartica sučelja za opremu (IE) koje opskrbljuju opremu (E) izravno, preko poljske sabirnice (B1), na temelju naredaba primljenih iz upravljača opreme i primanja upravljačkih signala iz poljskih senzora, prebacujući ih na upravljač, gdje navedeni sustav ima:
The composition of any preceding claim, wherein the bacterial strain is lyophilised and/or is viable. 
bakterijska vrsta je liofilizirana; i/ili bakterijska vrsta je održiva; i/ili
The antibody or antigen binding fragment thereof, or the antibody drug conjugate for use of claim 11 or 12, wherein the cancer is bladder cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, esophageal cancer, or head and neck cancer. 
Konjugat antitijela i lijeka za uporabu prema patentnom zahtjevu 19, gdje je rak rak gušterače, rak pluća, rak mjehura, rak kolona, rak jajnika, rak jednjaka, rak glave i vrata, ili rak dojke.
The vaccine comprises a peptide consisting of the amino acid sequence of SEQ ID NO 2, and a peptide consisting of the amino acid sequence of SEQ ID NO 3 and optionally at least one additional peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO 1, and SEQ ID NO 4 to SEQ ID NO 12 which are located and have been identified on primary glioblastoma cells. 
15. Peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 4 za uporabu u skladu s patentnim zahtjevom 13 ili 14, pri čemu se navedeno cjepivo nadalje sastoji od najmanje jednog dodatnog peptida odabranog iz SEQ ID br. 1 do SEQ ID br. 9, i SEQ ID br. 11 do SEQ ID br. 26.
Addition and then incomplete removal of SDS results in the biologically-active IL-2 microaggregates that are found in the PROLEUKIN™ product. Simple mixing of SDS and IL-2 at the concentrations found in the PROLEUKIN™ product does not give microaggregates. 
Dodavanje, a zatim nepotpuno odstranjivanje SDS rezultira biološki aktivnim mikroagregatima IL-2 koji se nalaze u proizvodu PROLEUKIN"M. Jedostavno miješanje SDS i IL-2 pri koncentracijama koje se nalaze u proizvodu PROLEUKINT"" ne daje mikroagregate.
The method according to claim 8, in which said infectious diseases are caused by a bacterium, fungus, protozoon or virus. 
Primjena prema zahtjevu 19, kod koje je u spomenutim bolestima infektivna tvar bakterija, gljivica, protozoa ili virus.
The compound of claim 1 in free form or in pharmaceutically acceptable salt form, in at least 99% enantiomeric excess. 
[image] dobiva putem reakcije spoja sljedeće formule (Va) u slobodnom obliku ili u obliku farmaceutski prihvatljive soli:
A process according to claim 11, wherein the product obtained after step a) is not isolated and steps a) and b) are performed in the same reactor. A process for manufacturing macitentan comprising 
Postupak prema jednom od zahtjeva 12 do 14, naznačen time, da se ne izolira produkt koji se dobiva nakon koraka a), a koraci a) i b) se izvode u istom reaktoru.
The pharmaceutical preparation for use according to claim 6, wherein the RPE cells are administered at a concentration of between about 333 viable RPE cells/µl and about 1,333 viable RPE cells/µl. 
Farmaceutski sastav prema zahtjevu 1, pri čemu je koncentracija spomenutih RPE stanica od oko 444 održivih RPE stanica/µL do oko 1766 održivih RPE stanica/µL, ili je barem oko 1,000 stanica/µL.
which comprises at least one Ig domain, and wherein the binding molecule capable of binding L1: 
(b) koja sadrže najmanje jednu Ig domenu, te naznačena time što je za vežuću molekulu koja se može vezati naLl:
The protein typically binds in the native state via hydrophobic groups located on the surface of the protein, and the native state is retained during the elution conditions. 
Protein se uobičajeno vezuje u svom nativnom stanju s pomoću hidrofobnih skupina koje se nalaze na njegovoj površini, a nativno stanje se održava tijekom faze ispiranja.
5) and counterparts thereof, wherein X8 and X35 are amino acid residues corresponding to Aib and X10 is an amino acid residue corresponding to glycine. 
5) i dijelovi koji ga nadopunjuju, gdje X i X* su amino kiselinski ostaci odgovarajući za Aib i X'" je amino kiselinski ostatak odgovarajući za glicin.
HPLC gradient is shown in table1. 
Spoj prikazan formulom D 3.
The compound of claim 1, wherein said compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je navedeni spoj odabran iz skupine koja sadrži:
The process according to claim 1, further comprising conducting step c) in a continuously operating cooling apparatus. 
Postupak prema zahtjevu 1, naznačen time da se korak c) provodi u uređaju za neprekidno hlađenje.
A pharmaceutical formulation according to claim 1 or claim 2, wherein the concentration of anti-IL-17 antibody is about 80 mg/mL. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 1, naznačena time što je koncentracija protutijela protiv IL-17 80 mg/ml.
The process of claim 2a wherein the suitable solvent is selected from the group consisting of acetone, methanol, ethanol, propanol, water, ethyl acetate, i -propanol, butanol, i -butanol, s -butanol, t -butanol, hexane, toluene, t -butyl-methyl ether, trichloroethane and the like, and mixtures thereof. 
Postupak iz zahtjeva 4 gdje se prikladno otapalo iz koraka a) bira iz skupine koja se sastoji od acetona, metanola, etanola, propanola, vode, etil acetata, i-propanola, butanola, i-butanola, s-butanola, f-butanola, heksana, toluena, f- butil-metil etera i trikloretana, i njihovih smjesa.
In a further embodiment, the phosphate is selected from a group consisting of a diphosphate and triphosphate. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran iz skupine koju čine: 2
Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above psychotic disorders, in particular schizophrenia. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psihotičnih poremećaja.
A method of delivering a molecule into a cell comprising contacting the cell with the complex of claim 5 or the nanoparticle of claim 5 or 6, wherein the complex or nanoparticle comprises the molecule, optionally wherein the contacting of the cell with the nanoparticle is carried out in vivo, ex vivo or in vitro; the cell is a granulocyte, a mast cell, a monocyte, a dendritic cell, a B cell, a T cell, or a natural killer cell, optionally wherein the molecule is a plasmid encoding a chimeric antigen receptor comprising an extracellular antigen-binding domain that specifically binds to a target antigen, a transmembrane domain, and an intracellular signaling domain, optionally wherein the target antigen is a cancer-associated antigen; and/or 
Metoda prema patentnom zahtjevu 15, pri čemu je stanica granulocit, mastocit, monocit, dendritička stanica, B stanica, T stanica ili stanica prirodni ubojica. Metoda prema patentnom zahtjevu 16, pri čemu je molekula je plazmid koji kodira himerni antigenski receptor, koji sadrži izvanstaničnu domenu vezanja antigena, koja se specifično veže na ciljni antigen, transmembransku domenu i unutarstaničnu signalnu domenu, opcijski je ciljni antigen antigen povezan na karcinom i/ili i) kompleksni spoj ili nanočestica nadalje sadrži siRNK; ili ii) metoda nadalje obuhvaća kontakt stanice s kompleksnim spojem prema patentnom zahtjevu 5 ili 7 ili nanočesticu prema bilo kojem od patentnih zahtjeva 6-9, pri čemu kompleksni spoj ili nanočestica sadrži siRNK; ili
Chloroform (99.8% D) or dimethyl sulfoxide (99.8% D) were used as solvents. 
Kao otapala su upotrijebljeni kloroform (99,8%D) ili dimetil sulfoksid (99,8%D).
capable of being cultured in suspension or as an adherent culture; 
- < sposobna je za kultivaciju u supenziji ili adherentnoj kulturi;
obtaining a cell from a transgenic mouse whose genome comprises an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with human Vλ and Jλ gene segments, wherein the human Vλ and Jλ gene segments are operably linked to a mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable region nucleic acid sequence fused with a mouse k constant region nucleic acid sequence; 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
The compound or composition for use according to claim 16 or 19, wherein said cancer is selected from lung cancer, head and neck cancer, pancreatic cancer, gastric cancer and brain cancer. 
Spoj prema bilo kojem od patentnih zahtjeva 1-3, ili njegova farmaceutski prihvatljiva sol, ili farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 4-6, za uporabu prema patentnom zahtjevu 7 ili 11, pri čemu je navedeni karcinom karcinom pluća, karcinom glave i vrata, karcinom pankreasa, karcinom želuca ili karcinom mozga.
A compound according to any one of claims 1 to 47 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy. 
Pripravak u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačen time, da se koristi u postupku liječenja metabolički-posredovanih poremećaja ljudskog ili životinjskog tijela terapijom.
The method according to claim 14, wherein the pharmaceutical composition is an anti-cancer vaccine. 
Farmaceutski sastav za uporabu prema zahtjevu 9, pri čemu je farmaceutski sastav cjepivo protiv karcinoma.
and R4 in combination with the nitrogen to which they are attached form a cyclic moiety selected from morpholino, pyrrolidinyl or piperazinyl. 
R* i R* u kombinaciji s dušikom na koji su vezani tvore cikličku skupinu odabranu od morfolino, pirolidinila ili piperazinila.
and R4, independently of one another, are a branched or straight-chain C1- to C10-alkyl radical, C5- to C8-cycloalkyl radical, aryl radical, heteroaryl radical or H; 
i R4, međusobno nezavisni, su granati ili linearni C1- do C10-alkil radikal, C5- do C8-cikloalkil radikal, aril radikal, heteroaril radikal ili H;
A pharmaceutical composition suitable for the oral treatment of multiple sclerosis consisting of dimethylfumarate and teriflunomide as active ingredients and one or more pharmaceutically acceptable excipients. Pharmaceutical composition according to claim 1, which is suitable for once daily administration. 
Kombinacija za uporabu za oralno liječenje multiple skleroze koja se sastoji od dimetilfumarata i lakvinimoda kao djelatnih sastojaka i jedne ili više farmaceutski prihvatljivih pomoćnih tvari, naznačena time što je kombinacija za primjenu dva puta dnevno, te pri čemu kombinacija sadrži:
The anti-CD20 antibody formulation of Claim 1, wherein the sodium chloride is present in an amount of 51mM. 
Formulacija protutijela an4-CD20 za uporabu prema zahtjevu 1, naznačena time, da je natrijev klorid prisutan u količini od 51 mM.
[Summary of Invention] 
(54) Naziv izuma:
A method according to claim 6, characterized in that the attachment is performed by pressing the tape (7) to an attachment with the aluminum foil lap's (5) polyethylene layer (8) at the same time as the aluminum foil (4), already secured to the mineral wool pipe section, is cut at the end that forms said aluminum foil lap for the mineral wool pipe section, and the polyethylene layer present thereon is melted. 
Metoda u skladu s patentnim zahtjevom 6, karakterizirana na način da je pričvršćivanje izvedeno pritiskom trake (7) na pričvršćenje s polietilenskim slojem (8) preklopa (5) obloge od aluminijske folije u isto vrijeme kao i obloga od aluminijske folije (4), već učvršćena za dio cijevi od mineralne vune, odrezane na kraju koji tvori navedeni preklop obloge od aluminijske folije dijela cijevi od mineralne vune, i ondje prisutan sloj polietilena je rastaljen.
The use of a compound of the formula (I) as defined in any one of 1 to 53 for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition arising from abnormal cell growth. 
(c) proizvodnju lijeka za prevenciju ili liječenje bolesti ili stanja koje proizlazi iz abnormalnog rasta stanica;
The method of claim 1 wherein said low levels of sICAM-1 means levels of fewer than 250 ng/ml. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedene niske razine sICAM-I1 znače razine ispod 250 ng/ml.
where R1-R13 are as defined herein; whereupon the compound of formula IC is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. 
R" u kojoj su R'-R'* kako je to ovdje definirano; nakon čega se spoj formule IC izolira kao slobodna baza ili sol njezina sol, kao što je to farmaceutski prihvatljiva njezina kisela dodatna sol
L1A is -L2A- or -L3A-L4A-L5A-; L2A is selected from the group consisting of an optionally substituted alkylene, an optionally substituted alkenylene, an optionally substituted heteroalkylene and an optionally substituted heteroalkenylene; 
LU je -L26. ili LALA, L* je odabran iz skupine koju čine po izboru supstituiran alkilen, po izboru supstituiran alkenilen, po izboru supstituiran heteroalkilen i po izboru supstituiran heteroalkenilen;
The isolated antibody for use according to claim 15, wherein the second agent is selected from the group consisting of a tyrosine kinase inhibitor, doxorubicin, temozolomide, cisplatin, carboplatin, nitrosourea, procarbazine, vincristine, hydroxyurea, 5-fluorouracil, cytosine arabinoside, cyclophosphamide, epipodophyllotoxin, carmustine, and lomustine. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da navedeno kemoterapeutsko sredstvo je odabrano iz skupine koju čine inhibitor kinaze tirozina, inhibitor kaskadne fosforilacije, post-translacijski modulator, inhibitor staničnog rasta ili stanične diobe, antimitotik, inhibitor signalne transdukcije, te njihove kombinacije.
obtaining all hybrid transform coefficients of a respective channel for the frame from the encoded audio data in the first audio block, and applying an inverse secondary transform to the hybrid transform coefficients to obtain inverse secondary transform coefficients, and obtaining primary transform coefficients from the inverse secondary transform coefficients for the respective channel in the respective audio block; and 
(i) dobivanje svih hibridnih transformacijskih koeficijenata za odgovarajući kanal za okvir iz kodiranih audio podataka u prvom audio bloku, te (ii) primjene inverzne sekundarne transformacije na hibridne transformacijske koeficijente da se dobiju inverzni sekundarni transformacijski koeficijenti, i (b) dobivanje primarnih transformacijskih koeficijenata iz inverznih sekundarnih transformacijskih koeficijenata za odgovarajući kanal u odgovarajućem audio bloku; (3) ako postupak kodiranja nije koristio adaptivnu hibridnu transformacijsku obradu za odgovarajući kanal, dobivanje primarnih transformacijskih koeficijenata za odgovarajući kanal pomoću dekodiranja kodiranih podataka u odgovarajućem audio bloku; te
A liver organoid according to any one of claims 11 to 15, which has one or more (e.g. 
Organoid jetre prema zahtjevu 9 ili zahtjevu 10, koji ima jednu ili više (npr.
A sealable container according to any preceding embodiment, further comprising at least one denesting recess, free of adhesive, adjacent a corner of the container. 
Posuda prema bilo kojem od prethodnih patentnih zahtjeva, koja dalje sadrži najmanje jedno udubljenje za odvajanje, bez prisutnosti ljepila, pored kuta posude.
A process for the preparation of compound of formula (I) as claimed in claim 1, which comprises reacting a compound of formula (III), with aryl sulfonyl chloride derivatives, in presence of suitable solvent at ambient temperature to obtain a compound of formula (I), wherein all substitutions are as defined in claim 1. 
* s. n Ra Ri (TED) sa derivatima aril sulfonil klorida, u prisutnosti pogodnog otapala kod temperature okoline da se dobije spoj sa formulom (1), pri čemu su sve supstitucije kako je definirano u zahtjevu 1.
The sustained-release composition for use according to any one of claims 1 to 8, wherein the composition is in a form selected from the group consisting of lozenges, (including but not limited to powder-based lozenges, syrup-based lozenges, granulated lozenges and lozenges with applicator/lollipops) and buccal tablets. 
Pripravak s produljenim oslobađanjem za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da je pripravak u obliku koji je odabran iz skupine koju čine praškaste pastile, sirupaste pastile i granulirane pastile, pastile sa aplikatorom/lizalice.
Titre (U/ml)=Reciprocal of the dilution at 50% of the response x pre-dilution The ST1P01/r-hIL-18BP final titre was calculated by averaging the 10 individual titres obtained in each experiment. 
Titar (U/ml)- Recipročno razrjeđenju kod 50% odgovora x za pred-razrjeđenje Konačan titar STIP01/r-hIL-18BP bio je izračunat iz prosjeka 10 pojedinačnih titara iz svakog eksperimenta.
or reacting a compound of general formula (III) with a compound of general formula (IV) or a salt thereof, 
reakciju spoja opće formule (III) sa spojem opće formule (IV) ili njegovom soli,